A phase II, open label, uncontrolled, multi center study to evaluate safety and immunogenicity of a commercially available surface antigen, inactivated, influenza vaccine, formulation 2006-2007, when administered to non-elderly adult and elderly subjects
Latest Information Update: 01 Jun 2011
Price :
$35 *
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 04 Jul 2007 New trial record.